120 related articles for article (PubMed ID: 28709401)
1. Signal transducer and activator of transcription 3 (STAT3) promoter methylation and expression in pituitary adenoma.
Valiulyte I; Steponaitis G; Skiriute D; Tamasauskas A; Vaitkiene P
BMC Med Genet; 2017 Jul; 18(1):72. PubMed ID: 28709401
[TBL] [Abstract][Full Text] [Related]
2. N-myc downstream-regulated gene 2 (NDRG2) promoter methylation and expression in pituitary adenoma.
Vaitkiene P; Valiulyte I; Glebauskiene B; Liutkeviciene R
Diagn Pathol; 2017 Apr; 12(1):33. PubMed ID: 28390436
[TBL] [Abstract][Full Text] [Related]
3. Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles.
Cheng S; Xie W; Miao Y; Guo J; Wang J; Li C; Zhang Y
J Transl Med; 2019 Dec; 17(1):407. PubMed ID: 31796052
[TBL] [Abstract][Full Text] [Related]
4. Expression of cold-inducible RNA-binding protein (CIRP) in pituitary adenoma and its relationships with tumor recurrence.
Wang M; Zhang H; Heng X; Pang Q; Sun A
Med Sci Monit; 2015 May; 21():1256-60. PubMed ID: 25934796
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas.
Miyake Y; Adachi JI; Suzuki T; Mishima K; Araki R; Mizuno R; Nishikawa R
J Neurooncol; 2019 Jan; 141(1):131-138. PubMed ID: 30392088
[TBL] [Abstract][Full Text] [Related]
6. A pilot genome-scale profiling of DNA methylation in sporadic pituitary macroadenomas: association with tumor invasion and histopathological subtype.
Ling C; Pease M; Shi L; Punj V; Shiroishi MS; Commins D; Weisenberger DJ; Wang K; Zada G
PLoS One; 2014; 9(4):e96178. PubMed ID: 24781529
[TBL] [Abstract][Full Text] [Related]
7. [Correlation between Expression of Signal Transducer and Activator of Transcription 3 and Pituitary Adenoma Subtypes].
Jiao YH; Liu XH; Dai CX; Cai F; Wang RZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2015 Dec; 37(6):693-7. PubMed ID: 26725392
[TBL] [Abstract][Full Text] [Related]
8. hTERT promoter methylation in pituitary adenomas.
Köchling M; Ewelt C; Fürtjes G; Peetz-Dienhart S; Koos B; Hasselblatt M; Paulus W; Stummer W; Brokinkel B
Brain Tumor Pathol; 2016 Jan; 33(1):27-34. PubMed ID: 26390879
[TBL] [Abstract][Full Text] [Related]
9. MMP-14 and TGFβ-1 methylation in pituitary adenomas.
Ruskyte K; Liutkevicienė R; Vilkeviciute A; Vaitkiene P; Valiulytė I; Glebauskiene B; Kriauciuniene L; Zaliuniene D
Oncol Lett; 2016 Oct; 12(4):3013-3017. PubMed ID: 27698891
[TBL] [Abstract][Full Text] [Related]
10. Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion.
Simpson DJ; Clayton RN; Farrell WE
Oncogene; 2002 Feb; 21(8):1217-24. PubMed ID: 11850841
[TBL] [Abstract][Full Text] [Related]
11. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
12. A gene expression profile of tumor suppressor genes commonly methylated in bladder cancer.
Christoph F; Hinz S; Kempkensteffen C; Weikert S; Krause H; Schostak M; Schrader M; Miller K
J Cancer Res Clin Oncol; 2007 Jun; 133(6):343-9. PubMed ID: 17160380
[TBL] [Abstract][Full Text] [Related]
13. Implications of MGMT methylation status in pituitary adenoma.
Arya S; Majaid MA; Shwetha SD; Sravani K; Arivazhagan A; Sampath S; Santosh V
Pathol Res Pract; 2014 Jul; 210(7):407-11. PubMed ID: 24690322
[TBL] [Abstract][Full Text] [Related]
14. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of expression and promoter hypermethylation of XAF1 in hepatitis B virus-associated hepatocellular carcinoma treated with transplantation.
Zhang F; Wu LM; Zhou L; Chen QX; Xie HY; Feng XW; Zheng SS
Ann Surg Oncol; 2008 Dec; 15(12):3494-502. PubMed ID: 18830757
[TBL] [Abstract][Full Text] [Related]
16. Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors.
Gao ZH; Suppola S; Liu J; Heikkilä P; Jänne J; Voutilainen R
J Clin Endocrinol Metab; 2002 Mar; 87(3):1170-6. PubMed ID: 11889182
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of signal transducer and activator of transcription 3 (STAT3) in pituitary adenomas.
Liu C; Nakano-Tateno T; Satou M; Chik C; Tateno T
Endocr J; 2021 Oct; 68(10):1143-1153. PubMed ID: 34248112
[TBL] [Abstract][Full Text] [Related]
18. Aberrant hypomethylated STAT3 was identified as a biomarker of chronic benzene poisoning through integrating DNA methylation and mRNA expression data.
Yang J; Bai W; Niu P; Tian L; Gao A
Exp Mol Pathol; 2014 Jun; 96(3):346-53. PubMed ID: 24613686
[TBL] [Abstract][Full Text] [Related]
19. STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells.
Zhang C; Guo F; Xu G; Ma J; Shao F
Oncol Rep; 2015 Apr; 33(4):1872-82. PubMed ID: 25653024
[TBL] [Abstract][Full Text] [Related]
20. Differential DNA methylome profiling of nonfunctioning pituitary adenomas suggesting tumour invasion is correlated with cell adhesion.
Gu Y; Zhou X; Hu F; Yu Y; Xie T; Huang Y; Zhao X; Zhang X
J Neurooncol; 2016 Aug; 129(1):23-31. PubMed ID: 27168190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
